12月中旬的深圳水贝，初冬的微凉被市场里的烟火气悄悄消融。水贝黄金珠宝交易市场，人流依旧熙攘，金光闪闪的饰件、耳畔萦绕着轻柔的询价声，唯 有柜台上方滚动的金价大屏，默默诉说着一场行业变革的悄然落地——区分"投资金"与"首饰金"的双标价显示，标注着黄金税改"满月"以来，这座中国最 大黄金集散地的理性与成长。 国际珠宝网 11月初，财政部、国家税务总局联合发布的黄金税收新政正式实施，这场被业内称为"黄金史上最严"的税改，以规范行业生态、厘清投资与消费边界为核 心，打破了水贝市场长期以来的经营惯性。一个月过去，实地探访发现，从初期的恐慌观望到如今的主动破局，从"价格战"的内卷到"价值战"的深耕，水 贝没有被变革击垮，反而在阵痛中孕育新生，在合规与温度的平衡中，走出了一条高质量发展的新路径。 税改"立规"：厘清边界，让黄金回归本真价值 税改的核心发力点，是厘清黄金"投资属性"与"消费属性"的边界，倒逼行业告别灰色地带，走向阳光化发展。这一变化，在水贝的金价波动与商户心声 中，显得尤为真切。 商户"破局"：多元突围，在变通中守护烟火生机 税改带来的冲击，最先传导至市场的每一位商户。对于依赖黄金零售、原料交易的中小商户而 ...

(本文来自第一财经) 比亚迪汽车官微发文称，比亚迪将以《汽车行业价格行为合规指南（征求意见稿）》为指引，持续优化 自身的价格管理和合规体系建设。承诺将严格落实规范价格竞争行为的要求，保障消费者的利益，坚决 杜绝任何形式的价格欺诈和不正当竞争行为。积极发挥行业示范引领作用，与全行业同仁携手共进，筑 牢行业合规经营秩序，推动构建协作共赢发展生态，助力汽车产业高质量发展。 ...

Core Viewpoint - 康泰医学 received a warning letter from the FDA regarding non-compliance with medical device quality system regulations for products exported to the U.S., which may impact its operations in the U.S. market [1][2] Company Summary - The warning letter was based on an FDA inspection conducted from June 9 to June 12, which identified multiple compliance issues related to production, packaging, storage, and installation of medical devices [2] - 康泰医学's U.S. market sales were approximately 114 million yuan in 2024, accounting for 23.8% of total revenue, with sales of 41.89 million yuan in the first half of the year, representing 19.26% of total revenue [3] - The company has 24 FDA-certified products and 3 products under registration, but the warning letter means a potential "window of inactivity" for its U.S. business until compliance issues are resolved [3] - In 2024, 康泰医学's revenue decreased by 35.76% to 480 million yuan, with a net loss of 77.9 million yuan, indicating that any impact on U.S. operations could exacerbate financial difficulties [4] Industry Summary - The frequency of FDA warning letters has increased, indicating rising compliance challenges for domestic medical device companies entering international markets [5][6] - In the 2024 fiscal year, the FDA issued 190 warning letters to drug and biological product manufacturers, up from 94 in 2023 and 74 in 2022, highlighting a trend of increasing regulatory scrutiny [5] - The issuance of warning letters can restrict product entry into the U.S. market and may affect the reputation of companies, leading to decreased confidence from U.S. customers and partners [6][7] - Frequent warning letters may compel Chinese pharmaceutical and medical device companies to enhance compliance management and quality systems, but could also harm the overall image of Chinese products in international markets [7]